



Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management

For Immediate Release

Toronto, Ontario – June 13, 2024 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is delighted to welcome Matt Dobson as the company's new Marketing Director, to accelerate the company's path to commercialization.

A seasoned professional in strategic marketing, Matt brings a wealth of experience from his tenure in various marketing roles and industries, including medical technology, diagnostics, therapeutics, technology and fast-paced consumer goods.

Based in the U.K., Matt will focus on developing actionable product development, marketing and sales programs built upon proprietary market, customer and user insights and ensuring optimal product-customer fit.

"Matt has excelled in past assignments and will be key in evolving Ventripoint to becoming a market driven organization," said Ventripoint's CEO Hugh MacNaught. "Our focus is developing actionable insights on how to drive adoption of Ventripoint's technology in routine clinical practice".

Added Dobson: "Ventripoint's proposition is unique, offering a revolutionary mix of accuracy, efficiency, and user-friendliness in cardiac imaging using artificial intelligence. This affordable tool promises to advance heart health management, making heart scans with cMRI levels of accuracy available to more people, at a fraction of the cost and with results in minutes."

Dobson's role begins immediately. His full bio is here (<https://www.linkedin.com/in/mattgdobson>)

For further information, please contact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.



Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.